Hospital Joins Pulmonary Fibrosis Foundation’s National Network
Rhode Island Hospital today announced that it has been selected as a member of the Pulmonary Fibrosis Foundation’s Care Center Network. As part of the network, the hospital will have access to a wealth of resources for both patients and caregivers and will collaborate with 39 other sites making up the network across the country to advance the care of people living with pulmonary fibrosis (PF).
“We are honored that the Pulmonary Fibrosis Foundation has recognized the quality of our programs and the expertise of our medical staff in treating patients with fibrotic lung disease,” said Margaret M. Van Bree, MHA, DrPH, president of Rhode Island Hospital.
Rhode Island Hospital submitted a joint application with Beth Israel Deaconess Medical Center, St. Elizabeth’s Medical Center and Massachusetts General Hospital. Together they comprise the Boston-Providence Pulmonary Fibrosis Care Centers and possess deep clinical and research capabilities and resources, according to Barry Shea, MD, director of the interstitial lung disease program at Rhode Island Hospital.
“For PF patients in this region, this collaboration holds much promise,” said Shea, who is also a member of the division of pulmonary, critical care and sleep medicine at University Medicine, and is an assistant professor at the Alpert Medical School of Brown University. “A diagnosis of PF can be devastating. While there are new treatments available which can slow the progression of this disease, there is no cure. And for many people, the side effects of these treatments can be worse than the disease itself. By conferring with other caregivers about our research and clinical experiences, we will be elevating the science behind the medical applications and collectively improving the quality of care for individuals afflicted with PF.”
Pulmonary Fibrosis Foundation’s Care Center Network includes leading medical centers with specific expertise in treating PF, a group of lung disorders that cause scarring in the lungs. In addition to being difficult to diagnose and manage, some forms of PF have survival rates of approximately three years following diagnosis.